Zepbound

Zepbound is the brand name for tirzepatide, a once-weekly subcutaneous injection manufactured by Eli Lilly. It was approved by the U.S. Food and Drug Administration in November 2023 for chronic weight management, and in 2024 picked up an additional indication for obstructive sleep apnea in adults with obesity.

Tirzepatide is the first and so far only drug in the dual GIP/GLP-1 receptor agonist class to reach the obesity market. It activates two separate gut-hormone pathways — glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) — which together slow gastric emptying, blunt appetite signals in the hypothalamus, and improve insulin sensitivity. Semaglutide-based drugs like Wegovy and Ozempic only hit the GLP-1 receptor, which is the mechanistic reason tirzepatide typically outperforms them on weight loss.

Zepbound shares its active ingredient with Mounjaro, Lilly's type 2 diabetes drug. They are the same molecule at the same doses; only the FDA-approved indication and the packaging differ. That matters for insurance: plans that exclude obesity drugs sometimes still cover Mounjaro for diabetes.

The flagship trial for Zepbound in obesity was SURMOUNT-1, a 72-week placebo-controlled study of 2,539 adults with BMI ≥30 (or ≥27 with a weight-related condition) and without diabetes. Published in the New England Journal of Medicine in 2022, SURMOUNT-1 showed mean body weight reductions of 15.0% at 5 mg, 19.5% at 10 mg, and 22.5% at 15 mg — versus 2.4% on placebo.

SURMOUNT-2 extended these results to adults with type 2 diabetes (about 15% mean weight loss), SURMOUNT-3 tested tirzepatide after an intensive lifestyle lead-in (18.4% additional loss after 72 weeks of drug), and SURMOUNT-4 studied what happens when patients stop the drug — about half the weight is regained within a year, reinforcing that obesity is a chronic condition requiring chronic treatment.

The direct head-to-head trial SURMOUNT-5 (May 2025) compared tirzepatide to semaglutide 2.4 mg (the Wegovy dose) over 72 weeks. Tirzepatide produced 20.2% weight loss versus 13.7% for semaglutide — a 47% relative advantage. For patients choosing between Zepbound and Wegovy, SURMOUNT-5 is the single most important piece of evidence.

Zepbound is injected subcutaneously (under the skin of the abdomen, thigh, or upper arm) once per week, on the same day each week. The drug comes as a single-dose pen; doses available are 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg.

The standard escalation schedule starts at 2.5 mg for 4 weeks, increases to 5 mg for 4 weeks, and then steps up by 2.5 mg every 4 weeks as tolerated until the maintenance target (5, 10, or 15 mg) is reached. Slow escalation is the single most effective strategy to minimize nausea.

Missed doses within 4 days of the scheduled day can be taken as soon as possible; beyond 4 days, skip and resume the normal schedule. Do not double dose. The pen must be refrigerated (36–46°F) but tolerates up to 21 days at room temperature.

Zepbound's safety profile mirrors the GLP-1 class. The most common side effects (>5% of patients in SURMOUNT-1) are nausea (29%), diarrhea (21%), constipation (17%), vomiting (10%), and injection-site reactions. These are dose-related, typically mild-to-moderate, and concentrated in the 8–12 weeks after each dose increase.

Less common but important risks include acute pancreatitis, gallbladder disease (cholecystitis is about 2–3x more likely than placebo), hypoglycemia when combined with insulin or sulfonylureas, acute kidney injury secondary to dehydration from vomiting/diarrhea, and diabetic retinopathy complications in patients with pre-existing disease.

Zepbound carries a boxed warning for thyroid C-cell tumors based on rodent data. It is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Pregnancy is a contraindication; the manufacturer recommends stopping the drug at least 2 months before a planned pregnancy.

A note on muscle mass: GLP-1 drugs cause weight loss that includes some loss of lean mass, roughly in the same proportion as diet-induced weight loss. Resistance training and adequate protein intake (1.2–1.6 g/kg/day) are the standard mitigations recommended by obesity medicine specialists.

The list price of Zepbound is approximately $1,086 per month for any dose. Almost nobody pays that.

Cash-pay through LillyDirect Self Pay: $349/month for single-dose vials (2.5, 5, 7.5, 10 mg), delivered directly from Lilly. This is the most common path for uninsured patients.

Commercial insurance with the Zepbound Savings Card: patients with commercial insurance that covers Zepbound can pay as little as $25 for a 1-month supply (up to $150 off per month for those without coverage through commercial plans, subject to Lilly's current offer terms — verify at Zepbound.com).

Medicare and Medicaid: Medicare Part D plans are prohibited from covering anti-obesity medications under current law — a significant access barrier. The Treat and Reduce Obesity Act (TROA) has been reintroduced in Congress multiple times but has not passed. Some state Medicaid programs cover Zepbound; check with your state.

Compounded tirzepatide: compounded versions were widely available during the FDA's 2023–2024 drug shortage declaration, but Zepbound was removed from the FDA shortage list in late 2024, which largely ended 503A and 503B compounding of identical-molecule tirzepatide. Some telehealth programs continue to offer non-identical "research-use" semaglutide and tirzepatide analogs; the safety and efficacy of these products is not established.

For a current view of cash, insurance, and compounded pricing across programs, see our GLP-1 program comparison or take the Sherpa Matcher.

The FDA label for Zepbound is adults with:

• BMI ≥ 30 (obesity), or
• BMI ≥ 27 with at least one weight-related condition (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease).

In practice, clinical judgment also weighs prior weight-loss attempts, readiness for long-term treatment, and cost. Zepbound is not approved for short-term cosmetic weight loss and is not FDA-approved for children (though pediatric trials are ongoing).

Zepbound is a particularly strong choice when maximum efficacy matters — for patients with severe obesity, metabolic syndrome, or who have plateaued on Wegovy or Ozempic. It is a weaker choice if injection aversion is a deal-breaker (consider the new Wegovy pill), if cash cost is a hard ceiling and a compounded program fits better, or if the patient has MTC/MEN 2 history.

Three typical paths:

1. In-person primary care or obesity medicine specialist. Your prescriber writes a script; you fill it at a pharmacy or via LillyDirect. Insurance prior authorization is common (usually requires documented BMI and a weight-loss attempt).

2. Telehealth program with brand-name Zepbound. Form Health, Mochi, Ro, and PlushCare all dispense FDA-approved Zepbound and handle the PA paperwork. Monthly fees range from $59 to $199 on top of the drug cost.

3. Cash via LillyDirect. Order 2.5–10 mg single-dose vials directly from Lilly at $349–$499/month. Requires a prescription from any licensed U.S. prescriber.

Whichever path you choose, the fastest way to start is a prescriber who already knows your history. The cheapest path depends heavily on your insurance — which is why we built the Matcher.